Soligenix Inc. (SNGX) 1.9200 $SNGX
Soligenix Announces $200,000 NIDCR SBIR Grant Award Supporting Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer
PR Newswire - Mon Apr 07, 6:15AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that the National Institute of Dental and Craniofacial Research (NIDCR) has awarded Soligenix a Small Business Innovation Research (SBIR) grant to support the conduct of its Phase 2, randomized, double-blind, placebo-controlled study evaluating SGX942, a first-in-class innate defense regulator, as a treatment for oral mucositis in patients undergoing chemoradiation therapy for head and neck cancer.
Vista Partners Publishes April 2014 Macroeconomic & Investment Newsletter
Marketwire - Fri Apr 04, 8:00AM CDT
Vista Partners ("Vista"
announced today that it published its FREE Macroeconomic & Investment Monthly Newsletter for the month of April. Each monthly newsletter from Vista contains macroeconomic thoughts from Principal Analyst Ross Silver, investment considerations, monthly highlights of each covered company and other broad based commentary.
Soligenix Reports Year-End 2013 Financial Results and Highlights Recent Accomplishments
PR Newswire - Wed Mar 26, 6:15AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today its financial results for the year ended December 31, 2013.
Vista Partners Initiates Coverage on Soligenix, Inc. (Ticker: SNGX); $5.50 Price Target
Marketwire - Tue Mar 18, 8:02AM CDT
Vista Partners announced today that it has initiated coverage on Soligenix, Inc. (OTCBB: SNGX) with a twelve-month price target of $5.50. Soligenix, Inc. is a New Jersey based clinical stage biopharmaceutical company committed to developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases. Ross Silver, Principal Analyst at Vista Partners, stated, "Soligenix has signed an exclusive worldwide collaboration deal with Intrexon Corporation ($2.9B mkt cap) (NYSE: XON) to develop a novel passive immunotherapy for Melioidosis. Melioidosis, also known as Bp, is an often deadly infectious disease caused by the bacterium, Burkholderia pseudomallei, with some symptoms similar to those of the flu and pneumonia. Melioidosis occurs in many different places around the globe, currently however it is of greatest concern in southeast-Asia and northern Australia, where public officials see it as a major threat to the health of the population." Mr. Silver continues, "The Company also has an exclusive commercial collaboration with SciClone Pharmaceuticals ($250M mkt cap) (NASDAQ: SCLN) in China for SGX942 in the treatment of oral mucositis." Mr. Silver concludes, "The Company boasts a diverse pipeline with nine prospective drug candidates. The science behind the Company's prospective therapies has been and continues to be validated by a number of significant, important and influential entities such as government organizations and major pharmaceutical companies. To date the Company has been awarded approximately $40M mainly through BARDA, NIH and FDA grants/contracts. The Company has up to approximately $34 million in active government contract and grant funding still available to support its associated research programs through 2018."
Soligenix to Present at 2014 World Vaccine Congress in Washington, DC
PR Newswire - Tue Mar 11, 6:00AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced today that its Chief Scientific Officer, Robert N. Brey, PhD, will give a presentation on the "Development of Thermostable Subunit Vaccines" at the 2014 World Vaccine Congress - Biotech Showcase on Tuesday, March 25, 2014. The presentation will take place at 2:10 PM Eastern Daylight Time (EDT) at the Marriott Wardman Park Hotel in Washington, DC, where Dr. Brey will, in part, review the Company's achievements to date with its ThermoVax(TM) vaccine heat stabilization technology.
Soligenix Inc receives USD300,000 NIAID SBIR grant to support further evaluation of SGX943 for the treatment of melioidosis
M2 - Mon Feb 17, 6:00AM CST
Biopharmaceutical company Soligenix Inc (OTC BB:SNGX) reported on Friday the receipt of USD300,000 Small Business Innovation Research (SBIR) grant to support further preclinical development of SGX943 for the treatment for melioidosis.
Soligenix Announces $300,000 NIAID SBIR Grant Award Supporting Further Evaluation of SGX943 as a Treatment for Melioidosis
PR Newswire - Fri Feb 14, 6:15AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that the National Institute of Allergy and Infectious Diseases (NIAID) has awarded Soligenix a Small Business Innovation Research (SBIR) grant to support further preclinical development of SGX943 as a treatment for melioidosis. The award will provide Soligenix with approximately $300,000 over one year to conduct the studies in collaboration with Tulane University.
Soligenix to Present at the 16th Annual BIO CEO & Investor Conference in New York City
PR Newswire - Wed Feb 05, 6:15AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that its President and Chief Executive Officer, Christopher J. Schaber, PhD, will give a corporate presentation at the 16th Annual BIO CEO Investor Conference in New York City, on Monday, February 10, 2014 at 3:00 PM Eastern Standard Time (EST). The presentation will take place in the Conrad room at the Waldorf Astoria.
B&B Music Lessons in the Mid-Atlantic Celebrates Ninth Anniversary
PR Newswire - Tue Feb 04, 7:30AM CST
B&B Music Lessons, based in Washington, D.C., is celebrating its ninth anniversary this March. Owners Brad Clements and Bhagwan Khalsa are pleased with the progress they've made since starting the business in 2005. The school currently has 65 teachers and 370 students, mostly age five to 15.
U.S. Chamber's Global IP Center Unveils 2014 International Intellectual Property Index
PR Newswire - Tue Jan 28, 11:01PM CST
Report Sheds Light on Progress, Deficiencies in 25 Countries' IP Environments, Including Select TPP Participants
Soligenix Inc awarded USD750,000 in non-dilutive financing from New Jersey's Technology Business Tax Certificate Transfer Program
M2 - Fri Jan 17, 10:43AM CST
Biopharmaceutical company Soligenix Inc (OTC BB:SNGX) reported on Thursday that it has received about USD750,000, net of transaction costs, in non-dilutive financing via the State of New Jersey's Technology Business Tax Certificate Transfer Program.
Soligenix Receives $750,000 in Non-Dilutive Financing from New Jersey's Technology Business Tax Certificate Transfer Program
PR Newswire - Thu Jan 16, 6:15AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well a developing several biodefense vaccines and therapeutics, announced today that it has recently received approximately $750,000, net of transaction costs, in non-dilutive financing via the State of New Jersey's Technology Business Tax Certificate Transfer Program (the Program).
Soligenix Announces Positive One-Year High-Temperature Stability Results with ThermoVax(TM) Vaccine Heat Stabilization Technology
PR Newswire - Wed Jan 15, 6:15AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today significant steps forward in the development of ThermoVax(TM), its proprietary vaccine thermostabilization platform technology. Recent studies have demonstrated the potential for heat-sensitive vaccines formulated using this technology to withstand temperatures exceeding 40 degrees Celsius (104 degrees Fahrenheit) for up to one year. The underlying work has been conducted with the Company's proprietary ricin toxin vaccine (RiVax(TM)) as part of a continuing program to evaluate the effectiveness of protein subunit vaccines to withstand extremes of temperature and other environmental stress conditions. These studies amplify and extend former evaluations that indicated retention of potency for at least six months at temperatures as high as 40 degrees Celsius, outside the range of typical vaccine storage conditions. The research and development of ThermoVax(TM) is currently being supported by a $9.4 million National Institute of Allergy and Infectious Disease (NIAID) grant to Soligenix for biodefense vaccines to prevent ricin toxin and anthrax exposure.
Soligenix to Present at the 2014 Biotech Showcase in San Francisco
PR Newswire - Thu Jan 09, 6:15AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that its President and Chief Executive Officer, Christopher J. Schaber, PhD, will give a corporate presentation at the 2014 Biotech Showcase in San Francisco, California on Tuesday, January 14, 2014 at 11:00 AM Pacific Standard Time (PST). The presentation will take place on the third floor of the Parc 55 Wyndham Hotel.
Courseload Releases Courseload Engage Learning Application for Faculty and Students
PR Newswire - Tue Jan 07, 9:00AM CST
Courseload, an institutional solution for the delivery and use of eTextbooks and digital course materials in higher education, today announced the release of Courseload Engage (Engage), its next generation application designed to enhance engagement and collaboration between students and instructors.
Soligenix Appoints Richard Straube, MD, as Chief Medical Officer
PR Newswire - Mon Jan 06, 6:15AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that it has appointed Richard Straube, MD, as its Senior Vice President and Chief Medical Officer. Dr. Straube is a board-certified pediatrician with clinical research experience in host-response modulation. He has had a long and distinguished career of more than 35 years in both academia and industry, most notably with Centocor, Ohmeda Pharmaceuticals, INO Therapeutics, and Stealth Peptides, Inc. Dr. Straube will lead Soligenix's clinical research with primary responsibility for the execution and completion of its multiple clinical programs, including its Phase 2 study in oral mucositis and its Phase 2/3 study in pediatric Crohn's disease.
Dai Telecom and Galooli Announce Cooperation
PR Newswire - Thu Dec 19, 3:00AM CST
Dai Telecom Ltd. and Galooli Ltd. today announced cooperation in the area of remote vehicle telematics. The cooperation centers on the integration of Dai Telecom's Roadstar advanced car phone with Galooli's remote performance monitoring platform - the ZON Control. This solution enables customers to use hands free smart phone capabilities in the car along with advanced remote tracking and fleet management solution, using neither extra hardware nor installation.
Soligenix Inc begins Phase 2 clinical trial of orBec for chronic GI GVHD under USD300,000 NCI grant
M2 - Tue Dec 03, 5:19AM CST
Biopharmaceutical company Soligenix Inc (OTC BB:SNGX) revealed on Monday the launch of a Phase 2, randomised, double-blind, placebo-controlled study evaluating orBec as a treatment for the gastrointestinal (GI) manifestations of chronic Graft-versus-Host disease (GVHD).
Soligenix Announces Initiation of a Phase 2 Clinical Trial of orBec® for the Treatment of Chronic GI GVHD
PR Newswire - Mon Dec 02, 6:15AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that it has initiated a Phase 2, randomized, double-blind, placebo-controlled study evaluating orBec® (oral beclomethasone 17,21-dipropionate or BDP) as a treatment for the gastrointestinal (GI) manifestations of chronic Graft-versus-Host disease (GVHD). The study is partially funded by the National Cancer Institute (NCI) which has awarded Soligenix a Small Business Innovation Research (SBIR) grant to support the conduct of a Phase 2 clinical trial. The award provides Soligenix with approximately $300,000 over a two-year period.
Soligenix Announces Initial $600,000 Investment and up to $10.6 Million Common Stock Purchase Agreement with Lincoln Park Capital Fund, LLC
PR Newswire - Thu Nov 21, 6:15AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that it signed a stock purchase agreement with Lincoln Park Capital Fund, LLC (LPC) providing an initial investment in Soligenix of $600,000 and the availability of additional periodic investments up to $10.0 million over a 36 month term.
Soligenix Announces $200,000 NIDCR SBIR Grant Award Supporting Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer
PR Newswire - Mon Apr 07, 6:15AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that the National Institute of Dental and Craniofacial Research (NIDCR) has awarded Soligenix a Small Business Innovation Research (SBIR) grant to support the conduct of its Phase 2, randomized, double-blind, placebo-controlled study evaluating SGX942, a first-in-class innate defense regulator, as a treatment for oral mucositis in patients undergoing chemoradiation therapy for head and neck cancer.
Vista Partners Publishes April 2014 Macroeconomic & Investment Newsletter
Marketwire - Fri Apr 04, 8:00AM CDT
Vista Partners ("Vista"
announced today that it published its FREE Macroeconomic & Investment Monthly Newsletter for the month of April. Each monthly newsletter from Vista contains macroeconomic thoughts from Principal Analyst Ross Silver, investment considerations, monthly highlights of each covered company and other broad based commentary. Soligenix Reports Year-End 2013 Financial Results and Highlights Recent Accomplishments
PR Newswire - Wed Mar 26, 6:15AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today its financial results for the year ended December 31, 2013.
Vista Partners Initiates Coverage on Soligenix, Inc. (Ticker: SNGX); $5.50 Price Target
Marketwire - Tue Mar 18, 8:02AM CDT
Vista Partners announced today that it has initiated coverage on Soligenix, Inc. (OTCBB: SNGX) with a twelve-month price target of $5.50. Soligenix, Inc. is a New Jersey based clinical stage biopharmaceutical company committed to developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases. Ross Silver, Principal Analyst at Vista Partners, stated, "Soligenix has signed an exclusive worldwide collaboration deal with Intrexon Corporation ($2.9B mkt cap) (NYSE: XON) to develop a novel passive immunotherapy for Melioidosis. Melioidosis, also known as Bp, is an often deadly infectious disease caused by the bacterium, Burkholderia pseudomallei, with some symptoms similar to those of the flu and pneumonia. Melioidosis occurs in many different places around the globe, currently however it is of greatest concern in southeast-Asia and northern Australia, where public officials see it as a major threat to the health of the population." Mr. Silver continues, "The Company also has an exclusive commercial collaboration with SciClone Pharmaceuticals ($250M mkt cap) (NASDAQ: SCLN) in China for SGX942 in the treatment of oral mucositis." Mr. Silver concludes, "The Company boasts a diverse pipeline with nine prospective drug candidates. The science behind the Company's prospective therapies has been and continues to be validated by a number of significant, important and influential entities such as government organizations and major pharmaceutical companies. To date the Company has been awarded approximately $40M mainly through BARDA, NIH and FDA grants/contracts. The Company has up to approximately $34 million in active government contract and grant funding still available to support its associated research programs through 2018."
Soligenix to Present at 2014 World Vaccine Congress in Washington, DC
PR Newswire - Tue Mar 11, 6:00AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced today that its Chief Scientific Officer, Robert N. Brey, PhD, will give a presentation on the "Development of Thermostable Subunit Vaccines" at the 2014 World Vaccine Congress - Biotech Showcase on Tuesday, March 25, 2014. The presentation will take place at 2:10 PM Eastern Daylight Time (EDT) at the Marriott Wardman Park Hotel in Washington, DC, where Dr. Brey will, in part, review the Company's achievements to date with its ThermoVax(TM) vaccine heat stabilization technology.
Soligenix Inc receives USD300,000 NIAID SBIR grant to support further evaluation of SGX943 for the treatment of melioidosis
M2 - Mon Feb 17, 6:00AM CST
Biopharmaceutical company Soligenix Inc (OTC BB:SNGX) reported on Friday the receipt of USD300,000 Small Business Innovation Research (SBIR) grant to support further preclinical development of SGX943 for the treatment for melioidosis.
Soligenix Announces $300,000 NIAID SBIR Grant Award Supporting Further Evaluation of SGX943 as a Treatment for Melioidosis
PR Newswire - Fri Feb 14, 6:15AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that the National Institute of Allergy and Infectious Diseases (NIAID) has awarded Soligenix a Small Business Innovation Research (SBIR) grant to support further preclinical development of SGX943 as a treatment for melioidosis. The award will provide Soligenix with approximately $300,000 over one year to conduct the studies in collaboration with Tulane University.
Soligenix to Present at the 16th Annual BIO CEO & Investor Conference in New York City
PR Newswire - Wed Feb 05, 6:15AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that its President and Chief Executive Officer, Christopher J. Schaber, PhD, will give a corporate presentation at the 16th Annual BIO CEO Investor Conference in New York City, on Monday, February 10, 2014 at 3:00 PM Eastern Standard Time (EST). The presentation will take place in the Conrad room at the Waldorf Astoria.
B&B Music Lessons in the Mid-Atlantic Celebrates Ninth Anniversary
PR Newswire - Tue Feb 04, 7:30AM CST
B&B Music Lessons, based in Washington, D.C., is celebrating its ninth anniversary this March. Owners Brad Clements and Bhagwan Khalsa are pleased with the progress they've made since starting the business in 2005. The school currently has 65 teachers and 370 students, mostly age five to 15.
U.S. Chamber's Global IP Center Unveils 2014 International Intellectual Property Index
PR Newswire - Tue Jan 28, 11:01PM CST
Report Sheds Light on Progress, Deficiencies in 25 Countries' IP Environments, Including Select TPP Participants
Soligenix Inc awarded USD750,000 in non-dilutive financing from New Jersey's Technology Business Tax Certificate Transfer Program
M2 - Fri Jan 17, 10:43AM CST
Biopharmaceutical company Soligenix Inc (OTC BB:SNGX) reported on Thursday that it has received about USD750,000, net of transaction costs, in non-dilutive financing via the State of New Jersey's Technology Business Tax Certificate Transfer Program.
Soligenix Receives $750,000 in Non-Dilutive Financing from New Jersey's Technology Business Tax Certificate Transfer Program
PR Newswire - Thu Jan 16, 6:15AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well a developing several biodefense vaccines and therapeutics, announced today that it has recently received approximately $750,000, net of transaction costs, in non-dilutive financing via the State of New Jersey's Technology Business Tax Certificate Transfer Program (the Program).
Soligenix Announces Positive One-Year High-Temperature Stability Results with ThermoVax(TM) Vaccine Heat Stabilization Technology
PR Newswire - Wed Jan 15, 6:15AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today significant steps forward in the development of ThermoVax(TM), its proprietary vaccine thermostabilization platform technology. Recent studies have demonstrated the potential for heat-sensitive vaccines formulated using this technology to withstand temperatures exceeding 40 degrees Celsius (104 degrees Fahrenheit) for up to one year. The underlying work has been conducted with the Company's proprietary ricin toxin vaccine (RiVax(TM)) as part of a continuing program to evaluate the effectiveness of protein subunit vaccines to withstand extremes of temperature and other environmental stress conditions. These studies amplify and extend former evaluations that indicated retention of potency for at least six months at temperatures as high as 40 degrees Celsius, outside the range of typical vaccine storage conditions. The research and development of ThermoVax(TM) is currently being supported by a $9.4 million National Institute of Allergy and Infectious Disease (NIAID) grant to Soligenix for biodefense vaccines to prevent ricin toxin and anthrax exposure.
Soligenix to Present at the 2014 Biotech Showcase in San Francisco
PR Newswire - Thu Jan 09, 6:15AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that its President and Chief Executive Officer, Christopher J. Schaber, PhD, will give a corporate presentation at the 2014 Biotech Showcase in San Francisco, California on Tuesday, January 14, 2014 at 11:00 AM Pacific Standard Time (PST). The presentation will take place on the third floor of the Parc 55 Wyndham Hotel.
Courseload Releases Courseload Engage Learning Application for Faculty and Students
PR Newswire - Tue Jan 07, 9:00AM CST
Courseload, an institutional solution for the delivery and use of eTextbooks and digital course materials in higher education, today announced the release of Courseload Engage (Engage), its next generation application designed to enhance engagement and collaboration between students and instructors.
Soligenix Appoints Richard Straube, MD, as Chief Medical Officer
PR Newswire - Mon Jan 06, 6:15AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that it has appointed Richard Straube, MD, as its Senior Vice President and Chief Medical Officer. Dr. Straube is a board-certified pediatrician with clinical research experience in host-response modulation. He has had a long and distinguished career of more than 35 years in both academia and industry, most notably with Centocor, Ohmeda Pharmaceuticals, INO Therapeutics, and Stealth Peptides, Inc. Dr. Straube will lead Soligenix's clinical research with primary responsibility for the execution and completion of its multiple clinical programs, including its Phase 2 study in oral mucositis and its Phase 2/3 study in pediatric Crohn's disease.
Dai Telecom and Galooli Announce Cooperation
PR Newswire - Thu Dec 19, 3:00AM CST
Dai Telecom Ltd. and Galooli Ltd. today announced cooperation in the area of remote vehicle telematics. The cooperation centers on the integration of Dai Telecom's Roadstar advanced car phone with Galooli's remote performance monitoring platform - the ZON Control. This solution enables customers to use hands free smart phone capabilities in the car along with advanced remote tracking and fleet management solution, using neither extra hardware nor installation.
Soligenix Inc begins Phase 2 clinical trial of orBec for chronic GI GVHD under USD300,000 NCI grant
M2 - Tue Dec 03, 5:19AM CST
Biopharmaceutical company Soligenix Inc (OTC BB:SNGX) revealed on Monday the launch of a Phase 2, randomised, double-blind, placebo-controlled study evaluating orBec as a treatment for the gastrointestinal (GI) manifestations of chronic Graft-versus-Host disease (GVHD).
Soligenix Announces Initiation of a Phase 2 Clinical Trial of orBec® for the Treatment of Chronic GI GVHD
PR Newswire - Mon Dec 02, 6:15AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that it has initiated a Phase 2, randomized, double-blind, placebo-controlled study evaluating orBec® (oral beclomethasone 17,21-dipropionate or BDP) as a treatment for the gastrointestinal (GI) manifestations of chronic Graft-versus-Host disease (GVHD). The study is partially funded by the National Cancer Institute (NCI) which has awarded Soligenix a Small Business Innovation Research (SBIR) grant to support the conduct of a Phase 2 clinical trial. The award provides Soligenix with approximately $300,000 over a two-year period.
Soligenix Announces Initial $600,000 Investment and up to $10.6 Million Common Stock Purchase Agreement with Lincoln Park Capital Fund, LLC
PR Newswire - Thu Nov 21, 6:15AM CST
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that it signed a stock purchase agreement with Lincoln Park Capital Fund, LLC (LPC) providing an initial investment in Soligenix of $600,000 and the availability of additional periodic investments up to $10.0 million over a 36 month term.
